Differentiated thyroid cancer lobectomy and radioiodine, a treatment suitable for all cases?

Nuclear Medicine Communications

Volumn 20, Issue 11, 1999, Pages 983-990

  Allan, E ^a   Owens, S E ^a   Waller, M L ^a,b  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b YORK HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

RADIOACTIVE IODINE;

ADJUVANT THERAPY; ARTICLE; CANCER SURVIVAL; CELL DIFFERENTIATION; DRUG EFFECT; HORMONAL REGULATION; HUMAN; LOBECTOMY; RADIATION DOSE; THYROID CANCER; THYROID HORMONE RELEASE; THYROIDECTOMY;

COMBINED MODALITY THERAPY; HUMANS; IODINE RADIOISOTOPES; RADIOMETRY; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 0032694836     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1080/00006231-199911000-00002     Document Type: Article

References (33)

1. Block MA. Management of carcinoma of the thyroid. Ann Surg 1977; 185: 133-144.
2. Buckwalter JA, Thomas CG Jr. Selection of surgical treatment for well differentiated thyroid carcinomas. Ann Surg 1972; 176: 565-578.
3. Mazzaferri EL, Young RL, Oertel JE, Kemmerer WT, Page CR Papillary thyroid carcinoma: The impact of therapy in 576 patients. Medicine 1977; 56: 171-196.
4. Thompson NW, Nishiyama RH, Harness JK. Thyroid carci-noma: Current controversies. Curr Probl Surg 1978; 15: 1-67.
5. Clark OH. Total thyroidectomy: The treatment of choice for patients with differentiated thyroid cancer. Ann Surg 1982; 196: 361-370.
6. Russell WO, Ibanez ML, Lee Clark R, White EC. Thyroid carcinoma: Classification, intraglandular dissemination and clinico-pathological study based upon whole organ section of 80 glands. Cancer 1963; 11: 1425-1460.
7. Crile G Jr, Antunez AR, Asselstyn CB Jr, Hawk WA, Skillern PG. The advantages of subtotal thyroidectomy and suppression of TSH in the primary treatment of papillary carcinoma of the thyroid. Cancer 1985; 55: 2691-2697.
8. Simpson WJ, Panzarella T, Carruthers JS, Gospodarowicz MK, Sutcliffe SB. Papillary and follicular thyroid cancer: Impact of treatment in 1578 patients. Int J Radiat Oncol Biol Phys 1988; 14: 1063-1075.
9. Riddell VH. Thyroidectomy: Prevention of bilateral recurrent nerve palsy. Results of idenfitication of the nerve over 23 consecutive years (1946-69) with a description of an additional safety measure. Br J Surg 1970; 57: 1-11.
10. Mazzaferri EL, Young RL. Papillary thyroid carcinoma: A 10 year follow-up report of the impact of therapy in 576 patients. Am J Med 1981; 70: 511-518.
11. Schroder DM, Chambors A, France CJ. Operative strategy for thyroid cancer: Is total thyroidectomy worth the price? Cancer 1986; 58: 2320-2328.
12. Beierwaltes WH, Rabbani R, Dmuchowski C, Lloyd RV, Eyre P, Mallette S. An analysis of ‘ablation of thyroid remnants’ with 1-131 in 511 patients from 1947-1984: Experience at University of Michigan. J Nucl Med 1984; 25: 1287-1293.
13. ICRP. Radiation dose to patients from radiopharmaceuticals. ICRP Publication 53. Oxford: Pergamon Press, 1988: 259-278.
14. Loevinger R, Budinger TF, Watson EE. MIRD primer for absorbed dose calculations. New York: Society of Nuclear Medicine, 1988.
15. Loevinger R, Japha RM, Brownell GL. Discrete radioisotope sources. In: Hine GJ, Brownell GL, eds. Radiation dosimetry. New York: Academic Press, 1956: 694-754.
16. Loevinger R, Holt JG, Hine GJ. Internally administered radionuclides. In: Hine GJ, Brownell GL, eds. Radiation dosimetry. New York: Academic Press, 1956: 868.
17. O’Connell MEA, Flower MA, Hinton PJ, Harmer CL, McCready VR. Radiation dose assessment in radioiodine therapy: Dose-response relationships in differentiated thyroid carcinoma using quantitative scanning and PET. Radiother Oncol 1993; 28: 16-26.
18. Heilman DE, Kartchner M, Van Antwerp JD, Salmon SE, Patton DD, O’Mara R. Radioiodine in the treatment of medullary carcinoma of the thyroid. J Clin Endocrinol Metab 1979; 48: 451-555.
19. Paterson R. The treatment of malignant disease by radio-therapy. London: Edward Arnold, 1963: 13.
20. Fajardo LF, Stewart JR. Pathogenesis of radiation-induced myocardial fibrosis. Lab Invest 1973; 29: 244-257.
21. Rooney P, Kumar S, Ponting J, Wang M. The role of hyalur-onan in tumour neovascularization (review). Int J Cancer 1995; 60: 632-636.
22. Garcia CJ, Daneman A, McHugh K, Chan H, Daneman D. Sonography in thyroid carcinoma in children. Br J Radiol 1992; 65: 977-982.
23. National Radiological Protection Board. Diagnostic and therapeutic uses of unsealed radioactive substances. In: Guidance notes for the protection of persons against ionizing radiations arising from medical and dental use. Didcot: NRPB, 1988: 57-59.
24. Nelson WR, Hirayama H, Rogers DW. The EGS4 code system. Stanford Linear Accelerator Centre Report 26. Stanford, CA: Stanford University, 1985.
25. Berger MJ. Energy deposition in water by photons from point isotropic sources. MIRD pamphlet No. 2. J Nucl Med 1968; 9 (suppl. 1): 15-25.
26. Stabin MG. Radiation dose to the upper spine from therapeutic administrations of iodine-131-sodium iodide. J Nucl Med 1993; 34: 695-696.
27. Leeper R. Controversies in the treatment of thyroid cancer: The New York Memorial Approach. Thyroid Today 1982; 4: 1-4.
28. Tubiana M. Role of radioiodine in the treatment of local thyroid cancer (editorial). Int J Radiat Oncol Biol Phys 1996; 36: 263-265.
29. Paryani SB, Chobe RJ, Scott W et al. Management of thyroid carcinoma with radioactive 131I. Int Radiat Oncol Biol Phys 1996; 36: 83-86.
30. Hall P, Holm LE, Lundell G et al. Cancer risks in thyroid cancer patients. Br J Cancer 1991; 64: 159-163.
31. Brincker H, Hansen HS, Andersen AP. Induction of leukaemia by 131I treatment of thyroid carcinoma. Br J Cancer 1973; 28: 232-237.
32. Brown AP, Greening WP, McCreedy VR, Shaw HJ, Harmer CL. Radioiodine treatment of metastatic thyroid carcinoma: The Royal Marsden Hospital experience. Br J Radiol 1984; 57: 323-327.
33. ICRP. Radionuclide transformations: Energy and intensity of emissions. ICRP Publication 38. Oxford: Pergamon Press.